PDS Biotechnology Corp (PDSB)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$0.220.00%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · PDSB
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance recently climbed back into the top half of its industry — confirming the recovery.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
PDSB — COO transition
Dated 2026-08-25
COO — Stephan Toutain: The Chief Operating Officer was terminated without cause, representing a sudden loss of a senior executive.
Why it matters: Good results could show PDS01ADC's value in treating metastatic colorectal cancer.
Supportive ifAnnouncement of good interim results from ongoing trials of PDS01ADC.
Worry ifAn announcement shares bad results or delays in trials.
Why it matters: Resolving the Nasdaq listing deficiency is critical for PDSB's market presence. It can stabilize share price.
Supportive ifA public announcement that PDSB has fixed its Nasdaq listing problem.
Worry ifMore notices from Nasdaq about listing problems.
Why it matters: Managing cash is very important for PDS Biotech's survival. A big drop in cash may show financial trouble.
Worry ifThe company reports an increase in cash reserves or a successful funding round.
Less concerning ifCash reserves go down more or the company says it needs money quickly.
Why it matters: Not following rules could lead to delisting and hurt investor trust.
Worry ifPDSB must meet Nasdaq rules in the next 3 months.
Less concerning ifMore notices of rule violations from Nasdaq.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$328 on $10,000 · ±3.3% | How much price usually moves either way. |
| Bad day | $891 loss on $10,000 · 8.9% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $8,597 loss on $10,000 · 86.0% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Restarting enrollment would signal progress in the pivotal trial for PDS0101 in head and neck cancer.
Supportive ifAn official announcement is out. Enrollment is back on for the VERSATILE-003 trial.
Worry ifFurther delays in enrollment or no updates on the trial status.
Why it matters: Completing acquisition agreements is key for PDSB's growth strategy. It can boost investor confidence.
Supportive ifA press release that confirms at least one acquisition deal is complete.
Worry ifNo news about completed acquisition deals in the next quarter.
Why it matters: Fixing the listing issue is important. It helps keep market access and investor trust.
Supportive ifThere is an announcement about meeting Nasdaq listing rules or a plan to fix the issue.
Worry ifNot fixing the issue or more notices from Nasdaq about compliance are concerns.
Why it matters: Updates on cash runway will show if the company can fund trials and operations.
Worry ifManagement reports cash runway extending beyond 12 months during the Q2 earnings call.
Less concerning ifManagement says cash runway is less than 6 months. This raises concerns about funding.
Why it matters: Burning cash could hurt operations and plans.
Worry ifCash balance reported below $5 million in the next quarterly update.
Less concerning ifCash balance stays the same or grows in the next update.
Why it matters: Starting the Phase 2b trial is key for advancing PDS0301. It shows commitment to the lead program.
Supportive ifAnnouncement of the Phase 2b trial initiation for PDS0301 within the next 6 months.
Worry ifDelay or cancellation of the Phase 2b trial initiation for PDS0301.
Why it matters: Partnerships could provide funding and support for PDS0101's development. This is crucial after ceasing internal investment.
Supportive ifAnnouncement of a strategic partnership for PDS0101 within the next 6 months.
Worry ifNo partnerships have been announced. The focus is only on PDS0301.